Methods for assessing inverse publication bias of adverse events
Contemporary Clinical Trials · 2024-10 · 145 · 107646
DOI: 10.1016/j.cct.2024.107646 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2024-10. Verfasst von Xing Xing und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, Johns Hopkins University, Maryland, MD, USA. Hauptthemen laut MEDLINE: Publication Bias. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NLM NIH HHS, NIMH NIH HHS, Arizona Biomedical Research Commission.
Themen: Patientensicherheit
Abstract (Originalsprache)
In medical research, publication bias (PB) poses great challenges to the conclusions from systematic reviews and meta-analyses. The majority of efforts in methodological research related to classic PB have focused on examining the potential suppression of studies reporting effects close to the null or statistically non-significant results. Such suppression is common, particularly when the study outcome concerns the effectiveness of a new intervention. On the other hand, attention has recently been drawn to the so-called inverse publication bias (IPB) within the evidence synthesis community. It can occur when assessing adverse events because researchers may favor evidence showing a similar safety profile regarding an adverse event between a new intervention and a control group. In comparison to the classic PB, IPB is much less recognized in the current literature; methods designed for classic PB may be inaccurately applied to address IPB, potentially leading to entirely incorrect conclusions. This article aims to provide a collection of accessible methods to assess IPB for adverse events. Specifically, we discuss the relevance and differences between classic PB and IPB. We also demonstrate visual assessment through contour-enhanced funnel plots tailored to adverse events and popular quantitative methods, including Egger's regression test, Peters' regression test, and the trim-and-fill method for such cases. Three real-world examples are presented to illustrate the bias in various scenarios, and the implementations are illustrated with statistical code. We hope this article offers valuable insights for evaluating IPB in future systematic reviews of adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biostatistics, Johns Hopkins University, Maryland, MD, USA.
- Clinical Transformation Center, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
- Department of Mathematics, College of Science and Arts, Najran University, Najran, Saudi Arabia.
- AbbVie Inc, North Chicago, IL, USA.
- Department of Biostatistics, School of Global Public Health, New York University, New York, NY, USA.
- Department of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA. Electronic address: lifenglin@arizona.edu.
Förderung
- NLM NIH HHS
- NIMH NIH HHS
- Arizona Biomedical Research Commission
- National Institute of Mental Health
- National Library of Medicine
Zitieren
APA
Xing, X., Xu, C., Al Amer, F. M., Shi, L., Zhu, J., & Lin, L. (2024). Methods for assessing inverse publication bias of adverse events. Contemporary Clinical Trials, 145, 107646. https://doi.org/10.1016/j.cct.2024.107646
Vancouver
Xing X, Xu C, Al Amer FM, Shi L, Zhu J, Lin L. Methods for assessing inverse publication bias of adverse events. Contemporary Clinical Trials. 2024;145:107646. doi:10.1016/j.cct.2024.107646
BibTeX
@article{Xing2024,
author = {Xing, Xing and Xu, Chang and Al Amer, Fahad M and Shi, Linyu and Zhu, Jianan and Lin, Lifeng},
title = {Methods for assessing inverse publication bias of adverse events},
journal = {Contemporary Clinical Trials},
year = {2024},
volume = {145},
pages = {107646},
doi = {10.1016/j.cct.2024.107646}
}
EUVIMED